Tie up between Sanofi and Merck for Vaccines Ends

Published On 2016-03-11 07:45 GMT | Update On 2016-03-11 07:45 GMT

French drug maker Sanofi and America's Merck are parting ways on their European Joint Venture focused on Vaccines. The decision to go their separate ways comes after a period of frenzied merger and acquisition activity in the global pharmaceuticals industry.

A statement released by the companies on Tuesday said 'after carefully considering our individual strategic priorities, alongside the economic and regulatory environments for vaccine operations in the European Union, we have mutually agreed that it is in our best interests to manage our vaccine product portfolios independently.'

According to Fast Track established in 1994, the joint venture was intended to unite the two company forces in developing and selling vaccines. However, the two now mutually feel that it’s time to end the venture.

While Sanofi’s Chief Executive, Olivier Brandicourt, is cutting costs and seeking to reshape the company’s portfolio. the French group, Merck has been seeking to exchange its animal medicines business, Merial, with a consumer health unit owned by Germany’s Ingelheim.

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Tie up between Sanofi and Merck for Vaccines Ends

Similar News